Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD11301 (resiquimod) gel in early-stage cutaneous T-cell lymphoma
2017-001677-16Phase 2Completed
- Sponsor
- Galderma
- Start
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of resiquimod in cutaneous T-cell lymphoma (CTCL) and mycosis fungoides (MF) (3 arms), sponsored by Galderma. Primary endpoint: Overall response rate (target lesions, Modified CAILS). Started Nov 2017; status: completed.
02
Drugs
resiquimod
03
Conditions
cutaneous T-cell lymphoma (CTCL)mycosis fungoides (MF)
Beyond the preview
Go deeper on 2017-001677-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001677-16.